Singapore, April 11, 2008: In order to strengthen the management to the export of drugs and medical devices, the State Food and Drug Administration (SFDA) in China is planning to cooperate with other related departments to carry out catalogue management to some drugs and medical devices under the Drug Administration Law of the People's Republic of China, Regulations for Supervision and Administration of Medical Devices and the Special Regulations of the State Council on Intensifying Safety Control of Food and Other Products.

 

The release noted that to prepare well for the implementation of the catalogue management, SFDA started to carry out investigation registration to some drugs, health foods and medical devices from April 3, 2008.

 

Products within the scope of the investigation registration include: gentamicin sulfate; atorvastatin and its salts; sildenafil and its salts; oseltamivir and its salts; cephalosporins and its finished dosage forms; human growth hormone and its finished dosage forms; glycerin (raw material); heparin, its salts and finished dosage forms; rtemisinin, its derivatives and finished dosage forms (including dihydroartemisinin, artesunate, artemether); Chinese proprietary medicines and health foods intended for erectile dysfunction or sexual enhancement; glucose test strips; condoms.